We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 320

Dentons' pick of global regulatory trends to watch in 2017
  • Dentons
  • Australia, Canada, China, European Union, Germany, Mexico, OECD, United Kingdom, USA
  • February 9 2017

Dentons’ team of regulatory lawyers from key jurisdictions around the world weigh in on regulatory trends to watch in 2017 in the US, Europe, the UK


Competitionantitrust law
  • Dentons
  • European Union, Germany, OECD, United Kingdom, USA, Australia, Canada, China
  • February 9 2017

In the wake of the 2016 elections, we now await the decision as to who will be the "antitrust guard" at the top of the US Department


Global Government Solutions 2016: Mid-Year Outlook
  • K&L Gates
  • Australia, Canada, European Union, Germany, Global, United Kingdom, USA
  • July 1 2016

As we issue this 2016 Mid-Year Outlook, the global community has begun to wrestle in earnest with the momentous political, economic, and doing


European Commission ups the cost of paying for delay
  • King & Wood Mallesons
  • Australia, European Union, USA
  • August 13 2012

On 25 July 2012, the EC alleged that Danish pharmaceutical company Lundbeck violated EU antitrust rules by colluding to prevent other pharma companies from marketing generic versions of its best-seller antidepressant, citalopram


Competition regulators continue their campaign against pharmaceutical companies
  • King & Wood Mallesons
  • Australia, USA
  • June 1 2011

Last month, the US Federal Trade Commission (FTC) released its findings on reverse payment settlements between pharmaceutical companies in the 2010 US fiscal year